You are here

Article Text

Article menu
Download PDFPDF
Poster exhibition Day 1
P77 L1CAM is an independent predictor of poor survival of endometrial cancer undergoing full lymphadenectomy and adjuvant chemotherapy
  1. A Oku1,2,
  2. H Asano1,2,
  3. KC Hatanaka3,4,
  4. R Matsuoka5,
  5. T Kato2,
  6. Y Konno2,
  7. T Mitamura2,
  8. K Ihira2,
  9. A Nozaki2,
  10. M Takeda2,
  11. N Kobayashi2,
  12. M Kudo2,
  13. Y Matsuno6,
  14. Y Hatanaka4 and
  15. H Watari1,2
  1. 1Deprtment of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine
  2. 2Department of Gynecology
  3. 3Clinical Research and Medical Innovation Center
  4. 4Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo
  5. 5Department of Pathology, International University of Health and Welfare, Mita Hospital, Tokyo
  6. 6Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

Abstract

Introduction/Background L1 cell adhesion molecule (L1CAM), a transmembrane protein of the immunoglobulin family that has been implicated in promoting cancer cell proliferation, invasion, migration, and metastasis, has been established as an important predictor of poor survival of early-stage endometrial cancer patients. We aimed to investigate whether L1CAM remains significant predictor of poor survival of the patients with endometrial cancer undergoing extensive surgical staging and adjuvant chemotherapy in this retrospective analysis.

Methodology We prepared tissue microarray (TMA) from surgical tissue specimens of 185 endometrial cancer patients who underwent full lymphadenectomy combined with adjuvant chemotherapy for patients at risk for recurrence, and evaluated expression of L1CAM by immunohistochemistry (IHC). L1CAM positivity was correlated with clinicopathological factors and its prognostic significance was investigated by multivariate analysis using Cox regression model.

Results Among 169 cases with over three years of follow-up period (median 95 months, 5–186 months), 53 cases (31.4%) showed positivity of L1CAM. L1CAM positivity was significantly correlated with non-endometrioid histology (p<0.0001), carcinosarcoma (p=0.0008), positive cytology (p=0.005), and p53 positivity (p<0.0001). L1CAM positive patients showed higher recurrent rate(15/53 (28.30%) vs 16/116 (13.79%), p=0.0277) and frequency of distant failure (11/14 (78.57%) vs 5/16 (31.25%), p=0.0361) than L1CAM negative patients. L1CAM positivity was a significant predictor of poor survival among advanced-stage patients (5-year OS; 49.0% vs 87.8%, p=0.0008, PFS; 35.7% vs 75.6%, p=0.0026), but not early-stage patients (5-year OS; 100% vs 98.7%, p=0.3456, PFS; 83.2% vs 93.3% p=0.2112). Multivariate analysis revealed that surgical stage and L1CAM positivity were independent predictors of poor survival. OS can be stratified into three groups by the combination of stage and L1CAM positivity.

Conclusion L1CAM is an independent predictor of poor survival of Japanese patients with advanced-stage endometrial cancer undergoing full lymphadenectomy and adjuvant chemotherapy. New treatment strategy should be developed for L1CAM positive patients with endometrial cancer.

Disclosure Nothing to disclose.

https://doi.org/10.1136/ijgc-2019-ESGO.139

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.